Abbreviations

AE
adverse event
ASPIRE
phase 3 trial of carfilzomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone
CI
confidence interval
CR
complete response
EORTC QLQ-C3
questionnaire developed to assess the quality of life of cancer patients
HR
hazard ratio
HRQoL
health-related quality of life
IV
intravenous
Dk
carfilzomib and dexamethasone
KRd
carfilzomib, lenalidomide and dexamethasone
MM
multiple myeloma
mPFS
median progression-free survival
MR
minimal response
ORR
overall response rate
PD
progressive disease
PFS
progression-free survival
PR
partial response
QoL
quality of life
RESPOND
phase 3 trial of carfilzomib and dexamethasone vs bortezomib and dexamethasone
Rd
lenalidomide and dexamethasone
sCR
stem cell transplant
SD
stable disease
SmPC
Summary of Product Characteristics
Vd
bortezomib and dexamethasone
VGPR
very good partial response

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis